Market Upgrades: Alnylam Pharmaceuticals Gains Analyst Support

Author: Owen Jenkins Updated: 08-04-2025 08:00 AM

Some Analysts Change Their Tune on Prominent Stocks

In the dynamic world of finance, analysts frequently adjust their ratings based on market trends and company performance. Recently, notable Wall Street analysts shifted their outlook on several stocks, and this article highlights the most significant upgrades and price target changes among them.

Federated Hermes, Inc. (FHI) Gets a Boost

JP Morgan analyst, Kenneth Worthington, upgraded Federated Hermes, Inc. (FHI) from Underweight to Neutral, increasing the price target from $40 to $54. On the last trading day, shares closed at $49.23, marking a promising outlook for investors. The overall sentiment suggests a growing confidence in the company’s performance.

Zevia PBC (ZVIA) Earns an Upgrade

Telsey Advisory Group's Dana Telsey has upgraded Zevia PBC (ZVIA) from Market Perform to Outperform, raising the price target from $3 to $5. Zevia's stock is currently trading at $3.04, reflecting a positive trajectory as analysts foresee increased market interest and potential growth in the beverage sector.

Alnylam Pharmaceuticals, Inc. (ALNY) Improving Prospects

In a notable shift, Wolfe Research's analyst Andy Chen upgraded Alnylam Pharmaceuticals, Inc. (ALNY) from Underperform to Peer Perform. The stock recently closed at $401.80, signaling a turnaround for investors, as the biopharmaceutical company continues to innovate and expand its product offerings.

Alamo Group Inc. (ALG) Shows Potential

Baird analyst Joseph Grabowski upgraded Alamo Group Inc. (ALG) from Neutral to Outperform, raising the price target from $209 to $260. The shares closed at $215.62, indicating a strong outlook as the company capitalizes on operational efficiencies and expanding market share in the machinery sector.

Apartment Investment & Management Company (AIV) Gets Recognized

Wolfe Research analyst Andrew Rosivach has upgraded Apartment Investment and Management Company (AIV) from Peer Perform to Outperform while maintaining a price target of $10. Recently traded at $8.39, this upgrade reflects a renewed interest in the real estate investment sector.

Investor Insights on ALNY Stock

If you're considering investing in Alnylam Pharmaceuticals, you may wonder what experts think about its prospects. With strong research backing and an improved rating, many analysts suggest that ALNY could be a wise investment choice.

Frequently Asked Questions

What recent changes have analysts made regarding Alnylam Pharmaceuticals?

Analysts upgraded Alnylam Pharmaceuticals from Underperform to Peer Perform, indicating a more optimistic outlook.

What is the current stock price of Alnylam Pharmaceuticals?

As of the latest trading session, Alnylam Pharmaceuticals shares closed at $401.80.

Which other stocks received upgrades from analysts?

Other stocks that received upgrades include Federated Hermes, Zevia PBC, Alamo Group, and Apartment Investment & Management Company.

What is the significance of these upgrades?

Upgrades can enhance investor confidence and typically lead to increased stock prices due to a more favorable analysis from experts in the field.

Where can I find more information about these stocks?

For more details, investors can consult financial news platforms or analyst rating websites dedicated to stock evaluations.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.